NCT07566390RecruitingPhase 1
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
A First in Human Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC0113-5840 in Participants With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 29 Apr 2026
- Start date
- 1 May 2026
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07566390
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 48
- From 1 May 2026 to the primary completion date, 31 Jan 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Lab values
- Glycosylated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) \[48 millimole per mole (mmol/mol)\] at screening.
Who the study is looking for
- Male or female
- Age 18-55 years (both inclusive) at the time of signing the informed consent.
- Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit and visit 2, day -1, as judged by the investigator.
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PAREXEL Intl - EPCU-Baltimore Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
| PAREXEL Glendale/LA EPCU Coordinator of this site? Confirm its status | Glendale | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.